EMVision Unlocks $1.17M Government Grant With No Dilution to Shareholders

By Josua Ferreira -

EMVision confirms $1.17M non-dilutive IGP grant instalment

EMVision Medical Devices Limited (ASX: EMV) has confirmed it has met the milestone requirements to trigger its next grant instalment under the Australian Government’s Industry Growth Program (IGP), with a payment of $1.17 million expected this month (May 2026).

The funding is non-dilutive, meaning no shareholder dilution and no debt obligation. The instalment forms part of the $5 million IGP Commercialisation and Growth Grant awarded to EMVision in June 2025 to support the global commercialisation of the First Responder Brain Scanner, the company’s lightweight pre-hospital brain scanning device designed for use in road and aeromedical settings.

Understanding IGP grant funding and what it means for EMVision investors

What is the Industry Growth Program?

The Industry Growth Program is an Australian Government initiative that provides funding to support the commercialisation and growth of innovative companies. Importantly, recipients do not give up equity and are not required to repay the funds.

For EMVision specifically, payments are made quarterly in advance, based on forecast eligible expenditure, adjusted for any unspent funds from prior periods. Each payment is subject to demonstrating satisfactory progress against agreed program milestones. This means funding is not automatic. EMVision was required to demonstrate continued execution on its First Responder product development and commercialisation programme to unlock this tranche.

EMVision’s grant funding position at a glance

  • Total IGP grant awarded: $5 million (June 2025)
  • Received prior to this instalment: $1 million
  • This instalment: $1.17 million
  • Remaining available: $2.83 million
Grant Stage Amount Status Cumulative Received
Initial instalment $1.00M Received $1.00M
Current instalment $1.17M Expected May 2026 $2.17M
Remaining available $2.83M Subject to milestones
Total IGP grant $5.00M Awarded June 2025

Milestone execution reinforces First Responder commercialisation progress

The triggering of this instalment reflects more than the passage of time. It demonstrates that EMVision has continued to execute against its agreed program milestones, satisfying the conditions required under the IGP grant agreement.

The First Responder Brain Scanner addresses a recognised gap in pre-hospital care: the ability to diagnose stroke in road and aeromedical settings, where speed is critical to patient outcomes. Stroke occurs when blood flow to the brain is interrupted, either by a blocked vessel (ischemic stroke) or bleeding into the brain (haemorrhagic stroke). Because these two stroke types require different treatments, rapid and accurate point-of-care diagnosis is clinically significant.

With $2.83 million remaining under the IGP, EMVision retains continued non-dilutive support for the program’s global commercialisation objectives. Each future instalment will similarly require satisfactory milestone progress before it is released.

What’s next for EMVision

Further grant tranches remain subject to continued milestone achievement under the IGP agreement, with the remaining $2.83 million providing ongoing non-dilutive support for the First Responder programme. EMVision’s broader mission is to help transform the timely diagnosis and treatment of stroke and other time-sensitive medical emergencies at the point-of-care. Continued execution against its programme milestones will be the key determinant of when, and whether, remaining funds are drawn down.

Don’t Miss the Next ASX Healthcare Breakthrough

Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis. Join 20,000+ investors already staying ahead of the market. Click the “Free Alerts” button at StockWire X to start receiving alerts the moment market-moving announcements drop.


Frequently Asked Questions

What is the Australian Government Industry Growth Program grant that EMVision received?

The Industry Growth Program (IGP) is an Australian Government initiative that provides non-dilutive, non-repayable funding to innovative companies to support commercialisation and growth. EMVision was awarded a $5 million IGP grant in June 2025 to support the global commercialisation of its First Responder Brain Scanner.

How much of the EMVision IGP grant has been received so far?

EMVision has received a total of $2.17 million to date, comprising an initial $1 million instalment and the current $1.17 million instalment expected in May 2026, leaving $2.83 million still available subject to future milestone achievement.

What is the EMVision First Responder Brain Scanner used for?

The First Responder Brain Scanner is a lightweight pre-hospital brain scanning device designed for use in road and aeromedical settings to rapidly diagnose stroke — distinguishing between ischemic (blocked vessel) and haemorrhagic (bleeding) stroke — where speed of diagnosis is critical to patient outcomes.

Does the EMVision IGP grant cause any shareholder dilution?

No, the IGP grant is non-dilutive, meaning EMVision does not need to issue new shares or take on debt to receive the funding, preserving existing shareholder value.

What milestones must EMVision meet to receive the remaining IGP grant funds?

Each future instalment under the IGP agreement requires EMVision to demonstrate satisfactory progress against agreed program milestones related to the First Responder Brain Scanner's development and commercialisation, with the remaining $2.83 million subject to continued execution.

Josua Ferreira
By Josua Ferreira
Partnership Director
Josua Ferreira holds a Bachelor of Commerce in Marketing and Advertising and brings a background in publication, business development, and ASX market storytelling. He has worked with listed companies across the resource sector and broader market, combining sharp commercial instincts with a genuine commitment to keeping investors informed.
Learn More
Companies Mentioned in Article

Breaking ASX Alerts Direct to Your Inbox

Join +20,000 subscribers receiving alerts.

Join thousands of investors who rely on StockWire X for timely, accurate market intelligence.

About the Publisher